PubRank

J Estapé

Author PubWeight™ 21.62‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Randomized trial of adjuvant chemotherapy with mitomycin plus ftorafur versus mitomycin alone in resected locally advanced gastric cancer. J Clin Oncol 1998 1.50
2 Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. J Clin Oncol 1996 1.13
3 Positive results of adjuvant mitomycin-C in resected gastric cancer: a randomised trial on 134 patients. Eur J Cancer 1993 1.02
4 Calcium supplementation and ototoxicity in patients receiving cisplatin. Br J Clin Pharmacol 1996 1.00
5 Cyclin D1 and retinoblastoma gene expression in human breast carcinoma: correlation with tumour proliferation and oestrogen receptor status. J Pathol 1997 0.99
6 Follow-up study in head and neck cancer: cure rate according to tumor location and stage. Oncology 1997 0.96
7 Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free melanoma patients. Clin Cancer Res 1999 0.96
8 p21WAF1/Cip1 is associated with cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma. J Pathol 1998 0.96
9 Breast cancer in Rubens paintings. Breast Cancer Res Treat 2001 0.95
10 C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients. Anticancer Res 1999 0.93
11 Age and clinical characteristics of 1433 patients with lung cancer. Age Ageing 1994 0.85
12 CYFRA 21-1 in lung cancer: comparison with CEA, CA 125, SCC and NSE serum levels. Int J Biol Markers 1994 0.85
13 Phase II trial of cisplatinum and etoposide in brain metastases of solid tumors. J Neurooncol 1997 0.85
14 Treatment of multiple myeloma in elderly people: long-term results in 178 patients. Age Ageing 1996 0.84
15 [Prognostic factors in uterine sarcomas: a 21-year retrospective study at the Clinic and Provincial Hospital of Barcelona]. Med Clin (Barc) 1998 0.83
16 Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated. J Clin Oncol 1996 0.83
17 Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients. Hematol J 2001 0.82
18 Chronic oral etoposide in advanced breast cancer. Cancer Chemother Pharmacol 1994 0.81
19 Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology). Leukemia 1998 0.81
20 CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial.(PETHEMA: Spanish Cooperative Group for the Study of Hematological Malignancies Treatment, Spanish Society of Hematology). Eur J Haematol 1996 0.80
21 TAG-72, CA 19.9 and CEA as tumor markers in gastric cancer. Acta Oncol 1994 0.78
22 Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3. Br J Cancer 1996 0.78
23 Six-year follow-up of primary small cell carcinoma of the esophagus showing a complete response: a case report. Jpn J Clin Oncol 1996 0.78
24 Age: a critical factor in cancer management. A prospective comparative study of 400 patients. Age Ageing 1999 0.76
25 Cancer chemotherapy and Raynaud's phenomenon. Ann Intern Med 1983 0.75
26 Phase II study of ACNU as second-line treatment in small-cell lung cancer. EORTC Lung Cancer Cooperative Group. Cancer Chemother Pharmacol 1992 0.75
27 [Use of fibrobronchoscopy in the therapeutic evaluation of small-cell pulmonary carcinoma]. Med Clin (Barc) 1983 0.75
28 Phase II study of ACNU in non-small-cell lung cancer: EORTC study 08872. Cancer Chemother Pharmacol 1991 0.75
29 [Cutaneous hyperpigmentation and vidarabine]. Med Clin (Barc) 1983 0.75
30 Phase II trial of UFT activity in pretreated breast cancer patients. Jpn J Clin Oncol 1993 0.75
31 [Role of systemic chemotherapy in the treatment of infiltrating cancer of the bladder]. Med Clin (Barc) 1989 0.75
32 [Cisplatin]. Med Clin (Barc) 1983 0.75
33 Survival after chemotherapy with cisplatin and infusion of bleomycin prior to local-regional treatment in pyriform sinus cancer. Tumori 1996 0.75
34 Phase II trial of carboplatin and etoposide activity in pretreated breast cancer patients. Am J Clin Oncol 1992 0.75
35 Adjuvant treatment in stage I and II malignant melanoma: a randomized trial between chemoimmunotherapy and immunotherapy. Dermatologica 1991 0.75
36 [Cerebral metastasis of melanoma: study of 48 patients]. Med Clin (Barc) 1993 0.75
37 [Primary malignant melanoma of the skin. Retrospective study of 375 cases. Clinical aspects and histology]. Med Clin (Barc) 1990 0.75
38 Endobronchial involvement in non-Hodgkin's lymphoma. Eur J Respir Dis 1986 0.75
39 Phosphohexose isomerase and carcinoembryonic antigen in the sera of patients with primary lung cancer. Int J Biol Markers 1989 0.75
40 Cross-resistance to alkylating agents in multiple myeloma. Cancer 1983 0.75
41 [Europe against cancer. Clinical conference]. Med Clin (Barc) 1989 0.75
42 Carboplatin plus ftorafur as a palliative treatment in locally advanced cancer of the oral cavity and lip. Am J Clin Oncol 1994 0.75
43 [Association of VCR-5FU-CYCLO-PDN in the treatment of disseminated carcinoma of the breast (author's transl)]. Med Clin (Barc) 1979 0.75
44 Intracavitary oxytetracycline in malignant pericardial tamponade. Oncology 1992 0.75
45 [Metoclopramide and cisplatin]. Med Clin (Barc) 1983 0.75
46 Neoadjuvant and adjuvant chemotherapy in the multidisciplinary treatment of oral cancer stage III or IV. Eur J Cancer B Oral Oncol 1996 0.75
47 VP16-213 and cyclophosphamide in advanced breast cancer. A phase II study. Cancer Chemother Pharmacol 1983 0.75
48 [Kaposi's angiosarcoma associated with bronchopulmonary carcinoma]. Med Clin (Barc) 1983 0.75